Edition:
United Kingdom

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

6.85USD
18 Jul 2018
Change (% chg)

$0.10 (+1.48%)
Prev Close
$6.75
Open
$6.99
Day's High
$6.99
Day's Low
$6.84
Volume
18,624
Avg. Vol
10,703
52-wk High
$7.85
52-wk Low
$4.75

Select another date:

Wed, Mar 7 2018

BRIEF-Mesoblast ‍Enters $75 Mln Non-Dilutive Credit Facility

* ENTERED US$75 MILLION NON-DILUTIVE, FOUR-YEAR CREDIT FACILITY WITH HERCULES CAPITAL

BRIEF-Mesoblast Posts ‍Qtrly Profit Attributable Of $13.7 Mln

* ‍QTRLY PROFIT ATTRIBUTABLE $13.7 MILLION VERSUS LOSS OF $20.1 MILLION ​ Source text for Eikon: Further company coverage:

BRIEF-Mesoblast Says ‍Primary Endpoint Achieved In A Phase 3 Cell Therapy Trial

* ‍PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN MESOBLAST'S PHASE 3 CELL THERAPY TRIAL FOR ACUTE GRAFT VERSUS HOST DISEASE​ Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

Mesoblast stem cell therapy meets goal of pediatric Graft vs. Host study

Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian company announced on Wednesday.

Mesoblast stem cell therapy meets goal of pediatric Graft vs Host study

Feb 21 Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian company announced on Wednesday.

Select another date: